Hangzhou Biotest Biotech688767.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 19, 2026, Hangzhou Biotest Biotech (688767.SH) trades at a P/E of 278.00x, P/B of 2.64x, P/S of 13.10x, and a dividend yield of 1.86%.
Longitudinal percentile comparison: P/E sits at the 97th percentile over the trailing 10Y window (vs. 95th percentile over 3Y); P/B sits at the 78th percentile over the trailing 10Y window (vs. 88th percentile over 3Y); P/S sits at the 77th percentile over the trailing 10Y window (vs. 62nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 94th percentile within its industry and the 94th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.86%, ranking at the 17th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 19.3 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Hangzhou Biotest Biotech operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 688767 · SSE: 688767 · 688767
Want the full picture on whether Hangzhou Biotest Biotech (688767.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 278.00 | ||||||
| P/B (MRQ) | 2.64 | ||||||
| P/S (TTM) | 13.10 | ||||||
| Dividend Yield | 1.86% | ||||||
| Buyback + Div Yield | 1.86% |